Common Contracts
9 similar Underwriting Agreement contracts by Acadia Pharmaceuticals Inc, Agile Therapeutics Inc, Aridis Pharmaceuticals, Inc., others
26,666,648 Shares of Common Stock Warrants to Purchase up to 13,333,324 Shares of Common Stock AGILE THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • October 8th, 2021 • Agile Therapeutics Inc • Pharmaceutical preparations • New York
Agile Therapeutics, Inc., a Delaware corporation (the "Company"), proposes, subject to the terms and conditions contained herein, to sell to you and the other underwriters named on Schedule I to this Agreement (the "Underwriters"), for whom you are acting as Representative (the "Representative"), an aggregate of 26,666,648 shares (the "Shares") of the Company's common stock, $0.0001 par value per share (the "Common Stock"), together with warrants to purchase an aggregate of 13,333,324 shares of Common Stock, in the form filed as an exhibit to the Registration Statement (as hereinafter defined) (the “Warrants” and collectively with the Shares, the “Securities”). The shares of Common Stock into which the Warrants are exercisable are hereinafter referred to as the “Warrant Shares.” The respective amounts of the Securities to be purchased by each of the several Underwriters are set forth opposite their names on Schedule I hereto. Each Share will be sold together with one-half of a Warrant
1,500,000 Shares INTRICON CORPORATION Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • August 20th, 2018 • Intricon Corp • Electronic components & accessories • New York
Underwriting AgreementUnderwriting Agreement • August 6th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Aridis Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as the representative, [•] shares of common stock, par value $0.001 per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [•] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). Certain terms used herein are defined in Section 20 hereof.
COMMON STOCK, $0.001 PAR VALUE PER SHARE UNDERWRITING AGREEMENTUnderwriting Agreement • October 6th, 2017 • LiveXLive Media, Inc. • Retail-eating places • New York
MultiVir Inc. [ ] Shares Common Stock (par value $0.001 per share) Underwriting AgreementUnderwriting Agreement • May 4th, 2015 • MultiVir Inc. • Pharmaceutical preparations • New York
MultiVir Inc., a corporation organized under the laws of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representative”) are acting as representative, [ ] shares of common stock, par value $0.001 per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to [ ] additional shares of Common Stock to cover over-allotments, if any (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representative as used herein shall mean you, as Underwriter, and the terms Representative and Underwriter shall mean either the singular or plural as the context requires. Cer
THERAPEUTICSMD, INC. COMMON STOCK UNDERWRITING AGREEMENTUnderwriting Agreement • February 17th, 2015 • TherapeuticsMD, Inc. • Pharmaceutical preparations • New York
3,703,704 Shares OHR PHARMACEUTICAL, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 6th, 2015 • Ohr Pharmaceutical Inc • Pharmaceutical preparations • New York
The Company represents and warrants to the several Underwriters, as of the date hereof and as of the Closing Date (as defined below), and agrees with the several Underwriters, that:
30,941,102 Shares of Common Stock Warrants to Purchase 22,011,265 Shares of Common Stock and Pre-Funded Warrants to Purchase 13,081,428 Shares of Common Stock MAST THERAPEUTICS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • November 7th, 2014 • Mast Therapeutics, Inc. • Pharmaceutical preparations • New York
ACADIA Pharmaceuticals Inc. 5,750,000 Shares Common Stock UNDERWRITING AGREEMENT dated April 4, 2007 Banc of America Securities LLC Lehman Brothers Inc. Deutsche Bank Securities Inc. Piper Jaffray & Co. JMP Securities LLC Rodman & Renshaw, LLCUnderwriting Agreement • April 5th, 2007 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • New York
The lock-up restriction described in the previous paragraph shall not apply to: (1) bona fide gifts to, or transfers to a trust for, the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (2) any shares of Common Stock sold pursuant to any 10b5-1 plan existing on or prior to the date hereof, and (3) the entering into a 10b5-1 plan during the Lock-Up Period so long as no shares of Common Stock are sold pursuant to such 10b5-1 plan during the Lock-Up Period; provided that in any transaction described in clause (1) above, (x) prior to such donation, transfer or distribution, such donee, transferee, or distributee shall execute and deliver to the Representatives a duplicate form of this lock-up agreement and (y) the undersigned shall not be required to, and shall not voluntarily, file a report under Section 16(a) of the Exchange Act. For purposes of this lock-up agreement, “immediate family” shall mean any relationship by blood, marriage or adoption,
